First-in-Human Single Ascending and Multiple Dose of GLPG0259

Lakefront Biotherapeutics NV32 enrolled

Overview

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral dose of GLPG0259 compared to placebo. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0259 after single and multiple oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

QUADRUPLE

Enrollment

Conditions

Healthy

Interventions

GLPG0259DRUG

single ascending doses, oral solution

placeboDRUG

single dose, oral solution

GLPG0259DRUG

multiple dose, oral solution, 5 days

placebo

Eligibility

Sex: MALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy male, age 18-50 years * BMI between 18-30 kg/m², inclusive. Exclusion Criteria: * significantly abnormal platelet function or coagulopathy * smoking * drug or alcohol abuse

Locations (1)

SGS Stuivenberg

Antwerp, Belgium

Outcomes

Primary Outcomes

Safety and tolerability of single and multiple dosing

Time frame: up to 10 days postdose

Secondary Outcomes

Pharmacokinetics of single and repeated doses

Time frame: up to 10 days postdose

Exploratory evaluation of TNF-alpha and IL6 in whole blood

Time frame: up to 12 hours postdose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.